Plasma levels of amyloid ? 40 and 42 are independent from ApoE genotype and mental retardation in down syndrome

Simona Cavani(Ente Ospedaliero Ospedali Galliera), Akira Tamaoka(University of Tsukuba), Aldo Moretti, Lucio Marinelli(University of Genoa), Giovanna Angelini, Sara Di Stefano, Giuseppe Piombo(Ente Ospedaliero Ospedali Galliera), Virginia Cazzulo, Sayoko Matsuno(University of Tsukuba), Shin'ichi Shoji(University of Tsukuba), Yoshiko Furiya(Osaka City University), D Zaccheo(University of Genoa), Francesca Dagna-Bricarelli(Ente Ospedaliero Ospedali Galliera), Massimo Tabaton(University of Genoa), Hiroshi Mori(Osaka City University)
American Journal of Medical Genetics
January 1, 2000
Cited by 34

Abstract

In Down syndrome (DS) brain an early, selective accumulation of amyloid beta (Abeta) peptides ending at residue 42 (Abeta42) occurs. Whether this event depends on an altered processing of amyloid beta precursor protein (APP) or on defective clearance is uncertain. To investigate this issue, we measured Abeta species 40 and 42 in plasma from 61 patients with DS, 77 age-matched normal controls, and 55 mentally retarded subjects without chromosomal abnormalities. The Abeta 40 and 42 plasma levels were then correlated with apolipoprotein E (apoE) genotypes in all groups of cases, and with I. Q. and Mini Mental Status Examination values in DS subjects. Both Abeta species were significantly elevated in DS compared to control groups, and the extent of their increase reflects that expected from APP gene overexpression. Plasma levels of Abeta 40 and 42 did not correlate with apoE genotypes in DS and control cases, and with the extent of mental retardation in DS subjects. The results indicate that accumulation and clearance of plasma and cerebral Abeta are regulated by different and independent factors.


Related Papers

No related papers found

Powered by citation graph analysis